WeVote
Log In

Bill

Bill

HB 1697

Ensuring timely, efficient, and evidence-based additions to newborn screenings.

2025-2026 Regular Session Introduced by Natasha Hill and 3 co-sponsors

HB 1697 creates a formal evidence-based process for systematically reviewing and adding conditions to Washington's newborn screening panel on a regular schedule.

Referred to Appropriations.
0
WeVote Research Nonpartisan
Bill Summary · HB 1697

Legislative bill overview

HB 1697 establishes a formal process for evaluating and adding conditions to Washington's newborn screening panel on a timely, evidence-based schedule. The bill creates criteria and procedures for reviewing which genetic, metabolic, and other serious conditions should be screened in newborns, moving beyond ad hoc additions.

Why is this important

Newborn screening can detect serious, treatable conditions within days of birth, preventing disability or death. Currently, the timeline and criteria for adding new screening tests lack formal structure, potentially creating gaps between scientific evidence supporting a test and its actual implementation, or conversely, adding costly tests without sufficient evidence.

Potential points of contention

  • Cost and insurance coverage: Expanding screening panels increases lab testing costs; unclear whether insurers or the state will bear these costs or how it affects families without coverage
  • Equity and access: Rural hospitals or smaller clinics may face implementation challenges; questions about whether all families receive equal access to expanded screening benefits
  • Evidence threshold debates: Disagreement over what constitutes sufficient evidence for adding a condition—some may want stricter standards (fewer additions, lower costs) while advocates for rare disease communities push for lower thresholds (broader screening, higher costs)

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.